Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, disclosed today that its Chairman and CEO, James A. Joyce, will be presented the “Spirit of India” award at the America India Foundation (AIF) annual gala on December 1, 2007. The event, sponsored by the Bill & Melinda Gates Foundation, honors American business leaders who have demonstrated a commitment to accelerating social and economic change in India. This year’s event, which is being held on World AIDS Day, places an increased emphasis on recognizing those working in the HIV-AIDS field. “I am truly honored to receive the AIF Spirit of India award,” stated Mr. Joyce. “It reflects the dedication of our team at Aethlon Medical and the support provided by shareholders who share our vision for treating infectious disease,” concluded Joyce. The AIF “Spirit of India” award is presented to two recipients each year. Ronald A. Rittenmeyer, the President and CEO of EDS has been named this year's other honoree. Past recipients of the award include:
- John Chambers, Chairman of CISCO
- Sy Sternberg, Chairman of New York Life
- Hector Ruiz, Chairman of AMD
- Charles Kaye, President of Warburg Pincus
- Ramalingam Raju, Chairman of Satyam
- Paul Otelini, CEO of Intel
- Nandan Nilekani, CEO of Infosys
This year’s event will be held at the Anaheim Hilton, located at 777 Convention Way in Anaheim, California. Tickets are tax-deductible and range from $500 - $10,000 per person. Additional details can be accessed online at www.aifoundation.org.
About AIF
AIF is the largest India centric charity in the USA. Founded at the initiative of President Bill Clinton, AIF is a trusted bridge for Americans to channel their philanthropy toward India. Since inception, AIF has raised over $45 million, and has invested in nearly 90 high-quality Indian NGOs who are working on primary education, women’s economic empowerment and HIV/AIDS. AIF has sent 169 Service Corps Fellows to serve for ten months with Indian NGOs, and the Digital Equalizer program has brought technology to touch the lives of over 570,000 students and 17,000 teachers in 1,400 schools across India. Former President Clinton serves as honorary Chairman of AIF.
About James A. Joyce
Jim Joyce is the Chairman, CEO, and founder of Aethlon Medical, a publicly traded company based in San Diego, California. Aethlon is the developer of the Hemopurifier®, a first-in-class medical device to treat infectious disease. In the United States, the Hemopurifier® is being advanced as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. The Hemopurifier® is also being advanced to target the treatment of medical conditions which represent a significant threat to the citizens of India. These conditions include Dengue Hemorrhagic Fever (DHF), HIV/AIDS, and Cancer. To support initiatives in India, Mr. Joyce has negotiated agreements resulting in: a research collaboration with the Government of India’s National Institute of Virology (NIV), the first-in-human clinical studies of the Hemopurifier® at the Apollo Hospital in Delhi; and, follow-on human studies now underway at the Fortis Hospital, also located in Delhi. He has also been instrumental in negotiating collaborations with researchers at The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), The Southwest Foundation for Biomedical Research (SFBR), The Battelle Biomedical Research Center, Commonwealth Biotechnologies, The University of Louisville, and Imquest Biosciences.
Mr. Joyce has been invited to speak on issues related to bioterrorism and emerging pandemic threats at federal, national and international forums. He has testified before congress and has discussed issues related to these topics on CNN, NBC, ABC, the BBC, and other media outlets. Mr. Joyce has been an active participant in efforts that expanded legislation in the United States to include medical devices and broad-spectrum treatments as part of government biodefense initiatives, and was invited by the Homeland Security Industry Association to serve as Co-Chair of the Bioterrorism/Chemical and Nuclear Security Task Force. He has served on the Project BioShield panel at The Federal Biodefense Research Conference, and the Biodefense Panel of the Homeland and Global Security Summit. Previously, Mr. Joyce founded and operated James Joyce & Associates, was founder and CEO of Mission Labs, Inc., and was a principal at London Zurich Securities, Inc. After graduating from University of Maryland, he was a member of the Denver Broncos Football Club in 1984-85.
About Aethlon Medical
Aethlon Medical is the developer of the Hemopurifier®, a first-in-class medical device to treat infectious disease. The Hemopurifier® addresses the largest opportunity in infectious disease, the treatment of drug and vaccine resistant viruses. Regulatory and commercialization initiatives in the United States are focused on bioterror threats, while international initiatives are directed towards naturally evolving pandemic threats, and chronic infectious disease conditions including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Collaborative studies to demonstrate utility of the Hemopurifier® are being conducted with researchers at the Government of India’s National Institute of Virology (NIV), The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Aethlon recently demonstrated safety of the Hemopurifier® in a 24-treatment human study and is now conducting follow-on human studies at the Fortis Hospital in Delhi, India. The Company has also submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) related to advancing the Hemopurifier® as a broad-spectrum treatment countermeasure against category “A” bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifier® technology can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company’s ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings.
Aethlon Medical, Inc.
Jeff Richardson, Senior Director, Communications
858-459-7800 x302
jrichardson@aethlonmedical.com